Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 9/20 | 0.71 |
| ▸ | ACVR1 | Q04771 | 11/20 | 0.62 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865570 | 1.00 | IGF1R (0.71) | IGF1RACVR1CCNE2CCNE1CDK2 | |
| SCHEMBL12338128 | 1.00 | IGF1R (0.71) | IGF1RACVR1CCNE2CCNE1CDK2 | |
| SCHEMBL14320155 | 0.91 | IGF1R (0.70) | IGF1RACVR1CCNE2CCNE1CDK2 | |
| SCHEMBL12337586 | 0.91 | IGF1R (0.70) | IGF1RACVR1CCNE2CCNE1CDK2 | |
| SCHEMBL12337769 | 0.90 | IGF1R (0.72) | IGF1RACVR1CCNE2CCNE1CDK2 | |
| SCHEMBL12923420 | 0.88 | IGF1R (0.69) | IGF1RACVR1CCNE2CCNE1CDK2 | |
| SCHEMBL13865558 | 0.88 | IGF1R (0.69) | IGF1RACVR1CCNE2CCNE1CDK2 | |
| SCHEMBL12337959 | 0.88 | IGF1R (0.69) | IGF1RACVR1CCNE2CCNE1CDK2 | |
| SCHEMBL12337549 | 0.85 | IGF1R (0.77) | IGF1RCCNE2CCNE1CDK2 | |
| SCHEMBL14313629 | 0.85 | IGF1R (0.77) | IGF1RCCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302747-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-29 | — | — | US | disclosed |
| US-20090239838-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-24 | — | — | US | disclosed |
| US-7534792-B2 | e.g. 1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-methylpyrrolidine-2-carboxamide; tyrosine kinase inhibitor; anticarcinogenic, antiproliferative agent, neurodegenerative diseases; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885ACVR1 2717/4885CCNE2 1617/4885 |
| US-20120302747-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885ACVR1 2717/4885CCNE2 1617/4885 |
| US-20090239838-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885ACVR1 2717/4885CCNE2 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.